Acceleron Pharma to Be Added to Russell 2000® Index
20 Diciembre 2013 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel protein therapeutics for cancer and rare
diseases, has been selected for addition to the Russell 2000®,
Russell 3000® and Russell Global® Indexes as part of Russell
Investments’ quarterly addition of select initial public offering
(IPO) companies. Acceleron will join these indexes after the NASDAQ
market closes on December 20, 2013.
Membership in the Russell 2000 Index results in automatic
inclusion in the appropriate growth and value style indexes. The
Russell 2000 Index measures the performance of the small-cap
segment of the market and is a subset of the Russell 3000, which
also serves as the U.S. component to the Russell Global Index.
Russell Investments determines membership for its equity indexes
primarily by objective market-capitalization rankings and style
attributes. Russell indexes are widely used by investment managers
and institutional investors for index funds and as benchmarks for
both passive and active investment strategies, and approximately
$4.1 trillion in assets are benchmarked to Russell Indexes.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
protein therapeutics for cancer and rare diseases. The company is a
leader in understanding the biology of the TGF-β protein
superfamily, a large and diverse group of molecules that are key
regulators in the growth and repair of tissues throughout the human
body, and in targeting these pathways to develop important new
medicines. Acceleron has built a highly productive R&D platform
that has generated innovative clinical and preclinical protein
therapeutic candidates with novel mechanisms of action. These
protein therapeutic candidates have the potential to significantly
improve clinical outcomes for patients with cancer and rare
diseases.
For more information, please visit www.acceleronpharma.com.
Acceleron PharmaSteven Ertel, 617-649-9234Senior Vice President
and Chief Business OfficerorMedia:Suda Communications LLCMaureen L.
Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc. (MM) Artículos de Noticias